Bristol Myers Squibb stock: RBC keeps USD 64.00 target for Bristol Myers Squibb stock

Published on 10/20/2026 at 16:32 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Bristol Myers posted USD 13.0 billion revenue in Q2 2026, up 6 percent year over year. Bristol Myers Squibb stock costs EUR 54.29 on October 20, 2026.

RBC keeps USD 64.00 target

RBC maintained its USD 64.00 price target and Sector Perform rating on October 19, 2026.
Second-quarter 2026 revenue rose 6 percent to USD 13.0 billion, while Growth Portfolio revenue increased 15 percent to USD 7.6 billion.
Bristol Myers Squibb stock costs EUR 54.29 at Lang & Schwarz on October 20, 2026 at 4:30 p.m. CEST.
Third-quarter 2026 results are scheduled for October 29, 2026.
Market capitalization stood at USD 124.7 billion on October 20, 2026.

Bristol Myers Squibb, US1101221083, Illustration mit AI erstellt.

Bristol Myers Squibb (ISIN US1101221083) has a USD 64.00 price target from RBC and a Sector Perform rating dated October 19, 2026. According to Fidelity, RBC expects the company to beat consensus revenue estimates in the third quarter. The stock was trading at EUR 54.29 at Lang & Schwarz on October 20, 2026 at 4:30 p.m. CEST.

Revenue growth shifts to newer medicines

Bristol Myers Squibb reported USD 12.97 billion in revenue for the second quarter of 2026, up 6 percent from the prior-year quarter. According to Yahoo Finance, Growth Portfolio revenue rose 15 percent to USD 7.6 billion, while the Legacy Portfolio declined 4 percent to USD 5.42 billion. The split matters because the newer portfolio is carrying more of the company growth as older products face competition.

Stock position and valuation

The Lang & Schwarz quote places the euro price within a broad trading frame corresponding to USD 42.52 to USD 68.64 for the 52-week range on October 20, 2026. Bristol Myers Squibb had a market capitalization of USD 124.7 billion and a price-to-earnings ratio of 13.51 on the same date. The company is listed on the NYSE under BMY, as identified on its investor-relations page.

Results date gives the next test

Bristol Myers Squibb is scheduled to report third-quarter 2026 results on October 29, 2026. The company announced the date in a release dated September 18, 2026, saying that management will discuss the results during an 8:00 a.m. ET conference call, according to Bristol Myers Squibb. RBC expects stronger sales from Eliquis, Revlimid, Breyanzi and Reblozyl to support the quarter, while upcoming milvexian trial data remain an important research event.

Comparison with peers

Bristol Myers Squibb: price-to-earnings ratio 13.51, market capitalization USD 124.7 billion. Merck & Co. (NYSE, USD): price-to-earnings ratio 118.82, market capitalization USD 364.9 billion. Eli Lilly and Company (NYSE, USD): price-to-earnings ratio 43.79, market capitalization USD 1.2 trillion.

What the target implies

RBC's USD 64.00 target sits 4.80 percent above the USD 61.07 primary-exchange price on October 20, 2026. That distance is modest beside the upcoming results date, so revenue delivery and the balance between newer and older medicines remain the measurable issues for the next report. Bristol Myers Squibb's second-quarter GAAP earnings per share were USD 1.62, while operating cash flow reached USD 3.4 billion for the quarter.

The further course of trading is shown by the continuously updated real-time quote of Bristol Myers Squibb stock.